Health Canada approves Vascepa to reduce the risk of CV events.- HLS Therapeutics.
HLS Therapeutics Inc.is pleased to announce that Health Canada has approved the use of Vascepa (icosapent ethyl) to reduce the risk of cardiovascular events (cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, coronary revascularization or hospitalization for unstable angina) in statin-treated patients with elevated triglycerides, who are at high risk of cardiovascular events due to established cardiovascular disease, or diabetes, and at least one other cardiovascular risk factor.
HLS in-licensed the exclusive rights to Vascepa for the Canadian market from Amarin Corporation in 2017.
"Cardiovascular disease is the leading cause of death worldwide and Vascepa provides a new treatment option for healthcare practitioners to enhance cardiovascular protection for the many Canadians at risk of a cardiac event," said Dr. Jean-Claude Tardif, Cardiologist and Director, Montreal Heart Institute Research Centre.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
3 mins